Perturbed Microbiota/Immune Homeostasis in Multiple Sclerosis
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received July 7, 2020
- Accepted in final form March 9, 2021
- First Published May 11, 2021.
Author Disclosures
- Delphine Sterlin, PharmD, PhD (delphine.sterlin{at}aphp.fr),
- Martin Larsen, PhD,
- Jehane Fadlallah, MD, PhD (martin.larsen{at}sorbonne-universite.fr),
- Christophe Parizot, MS,
- Marina Vignes, PharmD,
- Gaëlle Autaa, MS,
- Karim Dorgham, PhD,
- Catherine Juste, PhD,
- Patricia Lepage, PhD,
- Jennifer Aboab, MD,
- Savine Vicart, MD,
- Elisabeth Maillart, MD,
- Olivier Gout, MD,
- Catherine Lubetzki, MD, PhD (christophe.parizot{at}aphp.fr),
- Romain Deschamps, MD,
- Caroline Papeix, MD and
- Guy Gorochov, MD, PhD (rdeschamps{at}for.paris)
- Delphine Sterlin, PharmD, PhD (delphine.sterlin{at}aphp.fr),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Martin Larsen, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jehane Fadlallah, MD, PhD (martin.larsen{at}sorbonne-universite.fr),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christophe Parizot, MS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marina Vignes, PharmD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Gaëlle Autaa, MS,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Karim Dorgham, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Catherine Juste, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Patricia Lepage, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jennifer Aboab, MD,
Participation to advisory boards for Biogen during 2019 and Sanofi during 2020
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Savine Vicart, MD,
(1) Sanofi (2) Lupin
NONE
NONE
NONE
NONE
NONE
NONE
(1) Lupin
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Elisabeth Maillart, MD,
Ad Scientiam : scientific advisory board
NONE
(1) Biogen, funding for travel and lecture fees (2) Teva Pharmaceuticals, funding for travel and lecture fees (3) Sanofi-Genzyme, funding for travel and lecture fees (4) Roche, funding for travel and lecture fees (5) Novartis, funding for travel and lecture fees (6) Merck, funding for travel and lecture fees (7) Celgene-BMS, funding for lecture fees.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Olivier Gout, MD,
(1) Biogen (2) Genzyme (3) Teva (4) Merck Serono (5), Novartis (6) Medday
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Catherine Lubetzki, MD, PhD (christophe.parizot{at}aphp.fr),
BIOGEN, ROCHE,REWIND, GLIXOGEN
NONE
NONE
past associate editor BRAIN past- editorial board member of MSJ and MSJ and related disorders
NONE
NONE
NONE
BIOGEN, ROCHE, REWIND, GLIXOGEN
NONE
PhD support by BIOGEN
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Romain Deschamps, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Caroline Papeix, MD and
NONE
NONE
Novartis Biogen teva Roche Merck biogen Idec
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Guy Gorochov, MD, PhD (rdeschamps{at}for.paris)
Commercial entity: Scientific advisor for Luxia Scientific
NONE
NONE
Pharmacology, associate editor since 2020
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Guy Gorochov's research is supported by Fondation de France, « Tous unis contre le virus » framework Alliance (Fondation de France, AP-HP, Institut Pasteur) in collaboration with Agence Nationale de la Recherche (ANR Flash COVID19 program), by the SARS-CoV-2 Program of the Faculty of Medicine from Sorbonne University ICOViD programs, by the Programme Hospitalier de Recherche clinique PHRC-20-0375 COVID-19 (PI: GG)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Sorbonne Université (D.S., M.L., J.F., C.P., M.V., G.A., K.D., G.G.), Inserm, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), AP-HP Hôpital Pitié-Salpêtrière, France; Université Paris-Saclay (C.J., P.L.), INRAE, AgroParisTech, Micalis Institute, Jouy-en-Josas, France; Hôpital Ophtalmologique Adolphe de Rothschild (J.A., O.G., R.D.), Département de Neurologie, Paris, France; and Sorbonne Université (S.V., E.M., C.L., C.P.), Département de Neurologie, AP-HP Hôpital Pitié-Salpêtrière, Paris, France.
- Correspondence
Prof. Gorochov guy.gorochov{at}sorbonne-universite.fr
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Cutaneous α-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease
Dr. Rizwan S. Akhtar and Dr. Sarah Brooker
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Mucosal biopsy shows immunologic changes of the colon in patients with early MSAdrian Mathias Moser, Walter Spindelboeck, Heimo Strohmaier et al.Neurology: Neuroimmunology & Neuroinflammation, June 14, 2017 -
Article
Disease-modifying therapies alter gut microbial composition in MSIlana Katz Sand, Yunjiao Zhu, Achilles Ntranos et al.Neurology: Neuroimmunology & Neuroinflammation, October 26, 2018 -
Clinical/Scientific Notes
Fecal microbiota transplantation associated with 10 years of stability in a patient with SPMSSeraj Makkawi, Carlos Camara-Lemarroy, Luanne Metz et al.Neurology: Neuroimmunology & Neuroinflammation, April 03, 2018 -
Article
Induction of gut regulatory CD39+ T cells by teriflunomide protects against EAEJavier Ochoa-Repáraz, Sara L. Colpitts, Christopher Kircher et al.Neurology: Neuroimmunology & Neuroinflammation, October 12, 2016